Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 20
Filtrer
Plus de filtres











Gamme d'année
1.
CNS Neurosci Ther ; 30(8): e14883, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-39097919

RÉSUMÉ

BACKGROUND: Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, which promotes a sustained inflammatory environment in the central nervous system. Regulatory T cells (Tregs) play an important role in the control of inflammation and might play a neuroprotective role. Indeed, a decrease in Treg number and function has been reported in PD. In this context, pramipexole, a dopaminergic receptor agonist used to treat PD symptoms, has been shown to increase peripheral levels of Treg cells and improve their suppressive function. The aim of this work was to determine the effect of pramipexole on immunoregulatory Treg cells and its possible neuroprotective effect on human dopaminergic neurons differentiated from human embryonic stem cells. METHODS: Treg cells were sorted from white blood cells of healthy human donors. Assays were performed with CD3/CD28-activated and non-activated Treg cells treated with pramipexole at concentrations of 2 or 200 ng/mL. These regulatory cells were co-cultured with in vitro-differentiated human dopaminergic neurons in a cytotoxicity assay with 6-hydroxydopamine (6-OHDA). The role of interleukin-10 (IL-10) was investigated by co-culturing activated IL-10-producing Treg cells with neurons. To further investigate the effect of treatment on Tregs, gene expression in pramipexole-treated, CD3/CD28-activated Treg cells was determined by Fluidigm analysis. RESULTS: Pramipexole-treated CD3/CD28-activated Treg cells showed significant protective effects on dopaminergic neurons when challenged with 6-OHDA. Pramipexole-treated activated Treg cells showed neuroprotective capacity through mechanisms involving IL-10 release and the activation of genes associated with regulation and neuroprotection. CONCLUSION: Anti-CD3/CD28-activated Treg cells protect dopaminergic neurons against 6-OHDA-induced damage. In addition, activated, IL-10-producing, pramipexole-treated Tregs also induced a neuroprotective effect, and the supernatants of these co-cultures promoted axonal growth. Pramipexole-treated, activated Tregs altered their gene expression in a concentration-dependent manner, and enhanced TGFß-related dopamine receptor regulation and immune-related pathways. These findings open new perspectives for the development of immunomodulatory therapies for the treatment of PD.


Sujet(s)
Benzothiazoles , Neurones dopaminergiques , Oxidopamine , Pramipexole , Lymphocytes T régulateurs , Humains , Pramipexole/pharmacologie , Lymphocytes T régulateurs/effets des médicaments et des substances chimiques , Neurones dopaminergiques/effets des médicaments et des substances chimiques , Neurones dopaminergiques/métabolisme , Oxidopamine/toxicité , Benzothiazoles/pharmacologie , Techniques de coculture , Interleukine-10/métabolisme , Cellules cultivées , Neuroprotecteurs/pharmacologie , Agonistes de la dopamine/pharmacologie
2.
Rev Invest Clin ; 76(3): 159-169, 2024 Jul 18.
Article de Anglais | MEDLINE | ID: mdl-39025496

RÉSUMÉ

Background: Immunomodulatory drugs and immunotherapies are being evaluated in clinical trials for the treatment of neuroinflammation, as the latter is an essential mechanism for the development and progression of Parkinson's disease. Objective: The objective of the study is to review recent evidence on the evaluation of immunomodulators in randomized controlled clinical trials measuring improvement of motor symptoms. Methods: A meta-analysis of Movement Disorder Society-Unified Parkinson's disease Rating Scale (MDS-UPDRS III) scores extracted from seven articles selected after an online search of PubMed, Cochrane Library, and Clarivate's Web of Science for randomized controlled clinical trials published between 2000 and July 2023 was performed. The selected articles reported clinical trials evaluating the effects of specific immunomodulators or treatments with known effects on the immune system and inflammation. MDS-UPDRS III scores were reported in these studies, and the results of the placebo groups were compared with those of the treatment groups. Results: A total of 590 patients treated with immunomodulators and 622 patients treated with placebo were included. A test for heterogeneity yielded an I2 value > 50%. The mean standard difference for change in MDS-UPDR III score was -0.46 (CI [95%] = -0.90 - -0.02, p < 0.01). No significant differences were found in the change in mean MDS-UPDR III score between the treatment and placebo groups; however, two studies showed a trend toward separation from the mean. Conclusion: The immunomodulatory treatments included in this study showed no efficacy in improving motor symptoms in Parkinson's disease patients. Further clinical trials with larger patient populations are needed.


Sujet(s)
Agents immunomodulateurs , Maladie de Parkinson , Essais contrôlés randomisés comme sujet , Maladie de Parkinson/traitement médicamenteux , Maladie de Parkinson/thérapie , Humains , Agents immunomodulateurs/administration et posologie , Agents immunomodulateurs/usage thérapeutique , Agents immunomodulateurs/pharmacologie , Immunomodulation , Facteurs immunologiques/usage thérapeutique , Facteurs immunologiques/administration et posologie , Immunothérapie/méthodes
3.
Rev. invest. clín ; Rev. invest. clín;76(3): 159-169, May.-Jun. 2024. tab, graf
Article de Anglais | LILACS-Express | LILACS | ID: biblio-1569957

RÉSUMÉ

ABSTRACT Background: Immunomodulatory drugs and immunotherapies are being evaluated in clinical trials for the treatment of neuroinflammation, as the latter is an essential mechanism for the development and progression of Parkinson´s disease. Objective: The objective of the study is to review recent evidence on the evaluation of immunomodulators in randomized controlled clinical trials measuring improvement of motor symptoms. Methods: A meta-analysis of Movement Disorder Society-Unified Parkinson´s disease Rating Scale (MDS-UPDRS III) scores extracted from seven articles selected after an online search of PubMed, Cochrane Library, and Clarivate's Web of Science for randomized controlled clinical trials published between 2000 and July 2023 was performed. The selected articles reported clinical trials evaluating the effects of specific immunomodulators or treatments with known effects on the immune system and inflammation. MDS-UPDRS III scores were reported in these studies, and the results of the placebo groups were compared with those of the treatment groups. Results: A total of 590 patients treated with immunomodulators and 622 patients treated with placebo were included. A test for heterogeneity yielded an I2 value > 50%. The mean standard difference for change in MDS-UPDR III score was −0.46 (CI [95%] = −0.90 - −0.02, p < 0.01). No significant differences were found in the change in mean MDS-UPDR III score between the treatment and placebo groups; however, two studies showed a trend toward separation from the mean. Conclusion: The immunomodulatory treatments included in this study showed no efficacy in improving motor symptoms in Parkinson´s disease patients. Further clinical trials with larger patient populations are needed.

4.
J Neural Transm (Vienna) ; 131(8): 901-916, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38822829

RÉSUMÉ

Whilst the contribution of peripheral and central inflammation to neurodegeneration in Parkinson's disease and the role of the immune response in this disorder are well known, the effects of the anti-inflammatory response on the disease have not been described in depth. This study is aimed to assess the changes in the regulatory/inflammatory immune response in recently diagnosed, untreated PD patients and a year after. Twenty-one PD patients and 19 healthy controls were included and followed-up for 1 year. The levels of immunoregulatory cells (CD4+ Tregs, Bregs, and CD8+ Tregs); classical, nonclassical, and intermediate monocytes, and proinflammatory cells (Th1, Th2, and Th17) were measured by flow cytometry. Cytokine levels were determined by ELISA. Clinical follow-up was based on the Hoehn & Yahr and UDPRS scales. Our results indicate that the regulatory response in PD patients on follow-up was characterized by increased levels of active Tregs, functional Tregs, TR1, IL-10-producing functional Bregs, and IL-10-producing classical monocytes, along with decreased counts of Bregs and plasma cells. With respect to the proinflammatory immune response, peripheral levels of Th1 IFN-γ+ cells were decreased in treated PD patients, whilst the levels of CD4+ TBET+ cells, HLA-DR+ intermediate monocytes, IL-6, and IL-4 were increased after a 1-year follow-up. Our main finding was an increased regulatory T cell response after a 1-year follow-up and its link with clinical improvement in PD patients. In conclusion, after a 1-year follow-up, PD patients exhibited increased levels of regulatory populations, which correlated with clinical improvement. However, a persistent inflammatory environment and active immune response were observed.


Sujet(s)
Lymphocytes B régulateurs , Interleukine-10 , Maladie de Parkinson , Lymphocytes T régulateurs , Humains , Maladie de Parkinson/immunologie , Maladie de Parkinson/sang , Mâle , Femelle , Lymphocytes T régulateurs/immunologie , Interleukine-10/immunologie , Interleukine-10/sang , Lymphocytes B régulateurs/immunologie , Adulte d'âge moyen , Sujet âgé , Études de suivi
5.
J Neurochem ; 168(9): 2316-2334, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-38549444

RÉSUMÉ

The neurovascular unit, composed of vascular endothelium, vascular smooth muscle, extracellular matrix components, pericytes, astrocytes, microglia, and neurons, allows the highly regulated exchange of molecules and the limited trafficking of cells to the brain through coordinated signaling activity. The passage of peripheral immune cells to the brain parenchyma is observed when there is clear damage to the barriers of this neurovascular unit, as occurs in traumatic brain injury. The possibility of leukocyte infiltration to the brain in neurodegenerative conditions has been proposed. In this review, we focus on describing the evidence for peripheral immune cell infiltration to the brain in the two most frequent neurodegenerative diseases: Alzheimer's and Parkinson's diseases. In particular, we address the mechanisms that promote the passage of these cells into the brain under such pathological conditions. We also discuss the relevance of the resulting cellular interactions, which provide evidence that the presence of peripheral immune cells in the brain is a key point in these neurodegenerative diseases.


Sujet(s)
Maladie d'Alzheimer , Encéphale , Maladie de Parkinson , Humains , Maladie d'Alzheimer/immunologie , Maladie d'Alzheimer/anatomopathologie , Maladie de Parkinson/immunologie , Maladie de Parkinson/anatomopathologie , Animaux , Encéphale/immunologie , Encéphale/anatomopathologie , Leucocytes/immunologie , Leucocytes/anatomopathologie , Barrière hémato-encéphalique/immunologie , Barrière hémato-encéphalique/anatomopathologie
6.
Genes (Basel) ; 14(10)2023 10 07.
Article de Anglais | MEDLINE | ID: mdl-37895262

RÉSUMÉ

Parkinson's disease (PD) pathophysiology includes mitochondrial dysfunction, neuroinflammation, and aging as its biggest risk factors. Mitochondrial DNA copy number (mtDNA-CN) and telomere length (TL) are biological aging markers with inconclusive results regarding their association with PD. A case-control study was used to measure TL and mtDNA-CN using qPCR in PBMCs. PD patients were naive at baseline (T0) and followed-up at one (T1) and two (T2) years after the dopaminergic treatment (DRT). Plasmatic cytokines were determined by ELISA in all participants, along with clinical parameters of patients at T0. While TL was shorter in patients vs. controls at all time points evaluated (p < 0.01), mtDNA-CN showed no differences. An increase in mtDNA-CN and TL was observed in treated patients vs. naive ones (p < 0.001). Our statistical model analyzed both aging markers with covariates, showing a strong correlation between them (r = 0.57, p < 0.01), and IL-17A levels positively correlating with mtDNA-CN only in untreated patients (r = 0.45, p < 0.05). TL and mtDNA-CN could be useful markers for monitoring inflammation progression or treatment response in PD. DRT might modulate TL and mtDNA-CN, reflecting a compensatory mechanism to counteract mitochondrial dysfunction in PD, but this needs further investigation.


Sujet(s)
ADN mitochondrial , Maladie de Parkinson , Humains , ADN mitochondrial/génétique , Études cas-témoins , Variations de nombre de copies de segment d'ADN/génétique , Maladie de Parkinson/génétique , Télomère/génétique , Mitochondries/génétique , Marqueurs biologiques
7.
Rev Invest Clin ; 75(4): 193-202, 2023.
Article de Anglais | MEDLINE | ID: mdl-37607031

RÉSUMÉ

Background: In Parkinson's disease (PD), exosomes carry α-synuclein (α-syn), a fibrillar protein aggregates with potential value as a biomarker. Objective: Evidence on blood levels of exosomal α-syn in PD patients and controls was reviewed for their consistency. Methods: Thirty-six studies on exosomal α-syn concentrations in PD were identified in a systematic literature search and meta-analysis. Results: Both raw and ratio-adjusted blood exosomal α-syn levels were consistently higher in PD patients than in controls. The standardized mean difference (SMD) was 1.54 (0.18-2.90, CI95%, p < 0.01) and 1.53 (0.23-2.83, CI95%, p < 0.01), respectively. Conclusion: Our results suggest that exosomal α-syn concentrations could be a useful biomarker for PD.


Sujet(s)
Vésicules extracellulaires , Maladie de Parkinson , Humains , alpha-Synucléine , Marqueurs biologiques , Maladie de Parkinson/diagnostic
8.
Rev. invest. clín ; Rev. invest. clín;75(4): 193-202, Jul.-Aug. 2023. tab, graf
Article de Anglais | LILACS-Express | LILACS | ID: biblio-1515323

RÉSUMÉ

ABSTRACT Background: In Parkinson's disease (PD), exosomes carry α-synuclein (α-syn), a fibrillar protein aggregates with potential value as a biomarker. Objective: Evidence on blood levels of exosomal α-syn in PD patients and controls was reviewed for their consistency. Methods: Thirty-six studies on exosomal α-syn concentrations in PD were identified in a systematic literature search and meta-analysis. Results: Both raw and ratio-adjusted blood exosomal α-syn levels were consistently higher in PD patients than in controls. The standardized mean difference (SMD) was 1.54 (0.18-2.90, CI95%, p < 0.01) and 1.53 (0.23-2.83, CI95%, p < 0.01), respectively. Conclusion: Our results suggest that exosomal α-syn concentrations could be a useful biomarker for PD.

9.
Parasitol Res ; 122(7): 1489-1497, 2023 Jul.
Article de Anglais | MEDLINE | ID: mdl-37115316

RÉSUMÉ

The ability to modulate the host immune response has allowed some parasites to establish themselves in the tissues of an immunocompetent organism. While some parasite excretion/secretion products (ESPs) were recently reported to induce differentiation of regulatory T cells (Tregs), their identity is not known. This work is aimed to identify and characterize ESPs of Taenia crassiceps cysticerci linked with Treg induction in vivo. ESPs were obtained from cultures of T. crassiceps cysticerci and inoculated in mice, measuring Treg levels by flow cytometry. Proteins in ESPs were analyzed by electrophoresis; then, ESPs were classified as either differential or conserved. Differentially included proteins were MS-sequenced and functionally characterized. Only 4 of 10 ESPs induced Tregs. Proteins with catalytic activity and those involved in immunological processes predominated, supporting the idea that these molecules could play an important role in the induction of Tregs.


Sujet(s)
Parasites , Taenia , Animaux , Souris , Cysticercus , Lymphocytes T régulateurs , Cytométrie en flux , Souris de lignée BALB C
10.
Front Genet ; 12: 647487, 2021.
Article de Anglais | MEDLINE | ID: mdl-34149799

RÉSUMÉ

Systemic lupus erythematosus (SLE) is an autoimmune disease with a complex etiology. Various genetic factors are associated with susceptibility to developing SLE and contribute to its onset and progression. Different single-nucleotide polymorphisms (SNPs) have been associated with SLE in several populations. The rs12979860 SNP in interferon lambda 3/4 (IFNλ3/4) is significantly associated with SLE susceptibility in patients negative for nephritis in Taiwanese people, and interferon-stimulated genes (ISGs) are differentially expressed in normal liver by the rs12979860 genotype. This study aimed to investigate whether rs12979860 is associated with the presence of SLE and lupus nephritis in Mexican individuals as well as with the expression of several ISGs in SLE patients. In total, 439 SLE patients and 358 healthy donors were genotyped for rs12979860 using real-time PCR, and allelic discrimination plots were constructed. Additionally, peripheral blood mononuclear cells (PBMCs) were isolated from the venous blood of SLE patients by centrifugation (n = 78). The mRNA levels of 2'-5'-oligoadenylate synthetase like (OASL), myxovirus resistance 1 (MX1), 2'5'-oligoadenylate synthetase 1 (OAS1), interferon-stimulated gene 15 (ISG15) and lymphocyte antigen 6 complex, locus E (LY6E) were determined using real-time PCR. The distributions of rs12979860 genotypes and allele frequencies were compared between SLE patients and healthy donors; case-control analysis revealed that rs12979860 was not associated with SLE susceptibility (OR 1.18, 95% CI 0.97-1.45, p = 0.08) or with the risk for lupus nephritis (OR 0.913, 95% CI 0.590-1.411, p = 0.682). However, OASL expression levels in PBMCs were significantly different between rs12979860 genotypes in SLE patients: median OASL mRNA levels were significantly higher in patients carrying the CC genotype (197.10, IQR 71.10-411.17) than in those with CT/TT genotypes (173.75, IQR 58.80-278.75, p = 0.016). Our results suggest that the SNP rs12979860 does not play a relevant role in susceptibility to SLE in Mexican individuals. However, IFNλ3/4 genotypes appear to be associated with OASL expression in PBMCs from patients with SLE.

11.
Front Cell Infect Microbiol ; 11: 630583, 2021.
Article de Anglais | MEDLINE | ID: mdl-33928043

RÉSUMÉ

Murine cysticercosis by Taenia crassiceps is a model for human neurocysticercosis. Genetic and/or immune differences may underlie the higher susceptibility to infection in BALB/cAnN with respect to C57BL/6 mice. T regulatory cells (Tregs) could mediate the escape of T. crassiceps from the host immunity. This study is aimed to investigate the role of Tregs in T. crassiceps establishment in susceptible and non-susceptible mouse strains. Treg and effector cells were quantified in lymphoid organs before infection and 5, 30, 90, and 130 days post-infection. The proliferative response post-infection was characterized in vitro. The expression of regulatory and inflammatory molecules was assessed on days 5 and 30 post-infection. Depletion assays were performed to assess Treg functionality. Significantly higher Treg percentages were observed in BALB/cAnN mice, while increased percentages of activated CD127+ cells were found in C57BL/6 mice. The proliferative response was suppressed in susceptible mice, and Treg proliferation occurred only in susceptible mice. Treg-mediated suppression mechanisms may include IL-10 and TGFß secretion, granzyme- and perforin-mediated cytolysis, metabolic disruption, and cell-to-cell contact. Tregs are functional in BALB/cAnN mice. Therefore Tregs could be allowing parasite establishment and survival in susceptible mice but could play a homeostatic role in non-susceptible strains.


Sujet(s)
Lymphocytes T régulateurs , Taenia , Animaux , Immunité , Souris , Souris de lignée BALB C , Souris de lignée C57BL
12.
J Neuroimmunol ; 347: 577328, 2020 10 15.
Article de Anglais | MEDLINE | ID: mdl-32721557

RÉSUMÉ

Parkinson's disease (PD), the second most frequent neurodegenerative disease, has been linked to increased central and peripheral inflammation. Although the response of the immune system to dopaminergic treatment remains to be fully understood, dopaminergic agonists are known to exhibit immunoregulatory properties which may, at least in part, explain their therapeutic effect in PD. This highlights the need of analyzing immune parameters in longitudinal studies on PD patients receiving specific therapeutic regimes. In this work, PD patients were included in a two-year prospective study comparing the effect of levodopa alone and a levodopa/pramipexole combo therapy on several regulatory and pro-inflammatory immune cell populations. We demonstrated that PD patients show decreased circulating levels of several important regulatory subpopulations, as determined by flow cytometry. Notably, when administered alone, levodopa decreased the levels of functional Bregs and SLAMF1+ tolerogenic DCs and increased the levels of total and HLA-DR+ classical monocytes, while the pramipexole/levodopa combo may promote Treg- and tolerogenic DC-mediated regulatory responses. These results suggest that a regime based on levodopa alone may promote a pro-inflammatory-type response in PD patients, but when combined with pramipexole, it promotes a clinically beneficial regulatory-type environment.


Sujet(s)
Antiparkinsoniens/administration et posologie , Facteurs immunologiques/administration et posologie , Lévodopa/administration et posologie , Maladie de Parkinson/traitement médicamenteux , Pramipexole/administration et posologie , Association de médicaments , Études de suivi , Humains , Études longitudinales , Maladie de Parkinson/diagnostic , Maladie de Parkinson/immunologie , Études prospectives , Facteurs temps , Résultat thérapeutique
13.
Neuroimmunomodulation ; 26(3): 159-166, 2019.
Article de Anglais | MEDLINE | ID: mdl-31311029

RÉSUMÉ

OBJECTIVE: Parkinson's disease (PD) patients are usually treated with L-dopa and/or dopaminergic agonists, which act by binding five types of dopaminergic receptors (DRD1-DRD5). Peripheral immune cells are known to express dopamine receptors on their membrane surface, and therefore they could be directly affected by the treatment. Regulatory cells are the main modulators of inflammation, but it is not clear whether dopaminergic treatment could affect their functions. While only regulatory T cells (Tregs) have been proved to express dopamine receptors, it is not known whether other regulatory cells such as CD8regs, regulatory B cells (Bregs), tolerogenic dendritic cells, and intermediate monocytes also express them. METHODS: The expression of dopamine receptors in Tregs, CD8regs, Bregs, tolerogenic dendritic cells, and intermediate monocytes was herein evaluated. cDNA from 11 PD patients and 9 control subjects was obtained and analyzed. RESULTS: All regulatory cell populations expressed the genes coding for dopamine receptors, and this expression was further corroborated by flow cytometry. These findings may allow us to propose regulatory populations as possible targets for PD treatment. CONCLUSIONS: This study opens new paths to deepen our understanding on the effect of PD treatment on the cells of the regulatory immune response.


Sujet(s)
Lymphocytes B régulateurs/métabolisme , Lymphocytes T CD8+/métabolisme , Cellules dendritiques/métabolisme , Monocytes/métabolisme , Maladie de Parkinson/métabolisme , Récepteurs dopaminergiques/métabolisme , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Maladie de Parkinson/immunologie
14.
Neuroimmunomodulation ; 25(2): 103-109, 2018.
Article de Anglais | MEDLINE | ID: mdl-30041237

RÉSUMÉ

OBJECTIVE: The aim of this study is to analyze the immune-endocrine profile in neurocysticercosis (NC) patients resistant to cysticidal treatment. METHODS: The inflammatory and regulatory responses of 8 resistant NC patients with extraparenchymal parasites and 5 healthy controls were evaluated through flow cytometry. Serum interleukin levels were measured by ELISA and catecholamines levels by high performance liquid chromatography. RESULTS: Higher percentages of Tr1, CD4+CD25+FOXP3+CD127- and CD4+CD45RO+FOXP3HI were found in NC patients compared with healthy controls, but no difference was found in catecholamine levels. Antigen-specific proliferative immune response was observed in NC patients. Neither anti-inflammatory nor pro-inflammatory cytokines showed differences between patients and controls, but IL-6 levels were lower in treatment-resistant NC patients. In addition, TGFß showed a significant negative correlation with dopamine. CONCLUSIONS: Altogether, these results may point to a modulation of the neuroinflammation in these patients that could indirectly favor cysticercal survival in CNS microenvironment.


Sujet(s)
Antiparasitaires/usage thérapeutique , Immunité cellulaire/immunologie , Médiateurs de l'inflammation/sang , Médiateurs de l'inflammation/immunologie , Neurocysticercose/sang , Neurocysticercose/immunologie , Adulte , Sujet âgé , Antiparasitaires/pharmacologie , Marqueurs biologiques/sang , Catécholamines/sang , Catécholamines/immunologie , Femelle , Humains , Immunité cellulaire/effets des médicaments et des substances chimiques , Mâle , Adulte d'âge moyen , Neurocysticercose/traitement médicamenteux , Lymphocytes T/effets des médicaments et des substances chimiques , Lymphocytes T/immunologie , Lymphocytes T/métabolisme , Résultat thérapeutique
15.
Sci Rep ; 7(1): 12345, 2017 09 27.
Article de Anglais | MEDLINE | ID: mdl-28955045

RÉSUMÉ

Taeniids exhibit a great adaptive plasticity, which facilitates their establishment, growth, and reproduction in a hostile inflammatory microenvironment. Transforming Growth Factor-ß (TGFß), a highly pleiotropic cytokine, plays a critical role in vertebrate morphogenesis, cell differentiation, reproduction, and immune suppression. TGFß is secreted by host cells in sites lodging parasites. The role of TGFß in the outcome of T. solium and T. crassiceps cysticercosis is herein explored. Homologues of the TGFß family receptors (TsRI and TsRII) and several members of the TGFß downstream signal transduction pathway were found in T. solium genome, and the expression of Type-I and -II TGFß receptors was confirmed by RT-PCR. Antibodies against TGFß family receptors recognized cysticercal proteins of the expected molecular weight as determined by Western blot, and different structures in the parasite external tegument. In vitro, TGFß promoted the growth and reproduction of T. crassiceps cysticerci and the survival of T. solium cysticerci. High TGFß levels were found in cerebrospinal fluid from untreated neurocysticercotic patients who eventually failed to respond to the treatment (P = 0.03) pointing to the involvement of TGFß in parasite survival. These results indicate the relevance of TGFß in the infection outcome by promoting cysticercus growth and treatment resistance.


Sujet(s)
Cysticercus/immunologie , Interactions hôte-parasite/immunologie , Neurocysticercose/immunologie , Taenia solium/immunologie , Facteur de croissance transformant bêta/immunologie , Récepteur activine/génétique , Récepteur activine/immunologie , Récepteur activine/métabolisme , Animaux , Antigènes d'helminthe/génétique , Antigènes d'helminthe/immunologie , Antigènes d'helminthe/métabolisme , Antiparasitaires/pharmacologie , Antiparasitaires/usage thérapeutique , Cysticercus/génétique , Cysticercus/métabolisme , Modèles animaux de maladie humaine , Résistance aux substances/immunologie , Génome d'helminthe/immunologie , Protéines d'helminthes/génétique , Protéines d'helminthes/immunologie , Protéines d'helminthes/métabolisme , Humains , Souris , Souris de lignée BALB C , Neurocysticercose/liquide cérébrospinal , Neurocysticercose/traitement médicamenteux , Neurocysticercose/parasitologie , Transduction du signal/immunologie , Suidae , Taenia solium/génétique , Taenia solium/métabolisme , Facteur de croissance transformant bêta/liquide cérébrospinal , Facteur de croissance transformant bêta/métabolisme
16.
J Immunol Res ; 2016: 1720827, 2016.
Article de Anglais | MEDLINE | ID: mdl-27298831

RÉSUMÉ

T regulatory cells play a key role in the control of the immune response, both in health and during illness. While the mechanisms through which T regulatory cells exert their function have been extensively described, their molecular effects on effector cells have received little attention. Thus, this revision is aimed at summarizing our current knowledge on those regulation mechanisms on the target cells from a molecular perspective.


Sujet(s)
Immunomodulation , Lymphocytes T régulateurs/immunologie , Lymphocytes T régulateurs/métabolisme , Animaux , Communication cellulaire/immunologie , Cytokines/métabolisme , Cytotoxicité immunologique , Cellules dendritiques/immunologie , Cellules dendritiques/métabolisme , Granzymes/métabolisme , Humains , Système immunitaire/cytologie , Système immunitaire/immunologie , Système immunitaire/métabolisme , Immunité , Activation des lymphocytes/immunologie , Perforine/métabolisme , Transduction du signal
17.
Clin Dev Immunol ; 2013: 981468, 2013.
Article de Anglais | MEDLINE | ID: mdl-23762101

RÉSUMÉ

Regulatory T cells (Tregs) play a crucial role in immune homeostasis. Treg induction is a strategy that parasites have evolved to modulate the host's inflammatory environment, facilitating their establishment and permanence. In human Taenia solium neurocysticercosis (NC), the concurrence of increased peripheral and central Treg levels and their capacity to inhibit T cell activation and proliferation support their role in controlling neuroinflammation. This study is aimed at identifing possible mechanisms of Treg induction in human NC. Monocyte-derived dendritic cells (DC) from healthy human donors, cocultivated with autologous CD4(+) naïve cells either in the presence or absence of cysticerci, promoted CD25(high)Foxp3+ Treg differentiation. An increased Treg induction was observed when cysticerci were present. Moreover, an augmentation of suppressive-related molecules (SLAMF1, B7-H1, and CD205) was found in parasite-induced DC differentiation. Increased Tregs and a higher in vivo DC expression of the regulatory molecules SLAMF1 and CD205 in NC patients were also found. SLAMF1 gene was downregulated in NC patients with extraparenchymal cysticerci, exhibiting higher inflammation levels than patients with parenchymal parasites. Our findings suggest that cysticerci may modulate DC to favor a suppressive environment, which may help parasite establishment, minimizing the excessive inflammation, which may lead to tissue damage.


Sujet(s)
Cellules dendritiques/immunologie , Interactions hôte-parasite/immunologie , Neurocysticercose/immunologie , Neurocysticercose/parasitologie , Lymphocytes T régulateurs/immunologie , Taenia solium/immunologie , Adulte , Animaux , Antigènes CD/génétique , Antigènes CD/immunologie , Antigène CD274/génétique , Antigène CD274/immunologie , Différenciation cellulaire , Prolifération cellulaire , Techniques de coculture , Cellules dendritiques/parasitologie , Cellules dendritiques/anatomopathologie , Femelle , Expression des gènes , Humains , Lectines de type C/génétique , Lectines de type C/immunologie , Activation des lymphocytes , Mâle , Adulte d'âge moyen , Antigènes mineurs d'histocompatibilité , Monocytes/cytologie , Monocytes/immunologie , Neurocysticercose/anatomopathologie , Récepteurs de surface cellulaire/génétique , Récepteurs de surface cellulaire/immunologie , Membre-1 de la famille des molécules de signalisation de l'activation des lymphocytes , Lymphocytes T régulateurs/parasitologie , Lymphocytes T régulateurs/anatomopathologie
18.
Microbes Infect ; 15(6-7): 524-30, 2013 Jun.
Article de Anglais | MEDLINE | ID: mdl-23542217

RÉSUMÉ

Human neurocysticercosis (NC) is a clinically and radiologically heterogeneous disease caused by the establishment of Taenia solium larvae in the central nervous system. Herein, the immunological and endocrinological features involved in resistance to infection and severe forms of the disease are reviewed, and their clinical relevance is discussed.


Sujet(s)
Prédisposition aux maladies , Neurocysticercose/immunologie , Taenia solium/immunologie , Taenia solium/pathogénicité , Animaux , Humains
19.
Article de Anglais | VETINDEX | ID: vti-442070

RÉSUMÉ

Bovine cysticercosis, a cosmopolitan disease caused by Taenia saginata, leads to economic losses due to carcass devaluation at slaughter. Sanitary inspection at slaughterhouses, the routine diagnostic method in Brazil, lacks the necessary sensitivity to detect the mildly infected cattle that are typically encoutered in Brazil. In this study we have tested cattle sera from animals diagnosed as positive and negative by veterianry inspection for (1) anti-parasite antibodies using metacestodes antigens (T. solium vesicular fluid and T. saginata secretions) and (2) the HP10 secreted antigen of viable metacestodes. The cut-off values were calculated by ROC curve for intense and mild infections conditions, and by the classical method ( for negative samples). The sensitivity and specificity of these diagnostic tests were different depending on the assumed cut-off value and, importantly, whether the infection was mild or intense. In spite of these observations, however, such ELISA assays for serum antibodies and parasite antigens constitute an important tool for epidemiological porposes, and in establishing priorities for the control of bovine cysticercosis.


A cisticercose bovina, uma doença cosmopolita causada pelaTaenia saginata, resulta em perdas econômias devido á desvalorização de carcaças durante o abate. A inspeção sanitária nos frigoríficos, método de diagnóstico de rotina no Brasil, não possui sensibilidade necessária para detectar animais levemente infectados, os quais são tipicamente encontrados no Brasil. Neste estudo testou-se soro de animais diagnosticados positivos e negativos pela inspeção veterinária por (1) anticorpos anti-parasita usando antígenos de metacestóides (fluido vesicular deT. solium e secreções de T. saginata) e (2) antígeno secretado de metacestóides viáveis. Os pontos de corte foram calculados pela curva ROC, considerando condições de intensa e leve infeção, e pelo método clássico ( das amostras negativas). A sensibilidade e a especificidade dos testes diagnósticos foram diferentes dependendo do valor de ponto de corte assumido e, sobretudo, se a infecção era intensa ou leve. Apesar destas observações, no entanto, tanto o ensaio ELISA para anticorpos séricos quanto para antígeno de parasita constituem importante ferramenta para propósitos epidemiológicos e no estabelecimento de prioridades no controle da cisticercose bovina.

20.
Article de Anglais | VETINDEX | ID: vti-441996

RÉSUMÉ

Bovine cysticercosis, a cosmopolitan disease caused by Taenia saginata, leads to economic losses due to carcass devaluation at slaughter. Sanitary inspection at slaughterhouses, the routine diagnostic method in Brazil, lacks the necessary sensitivity to detect the mildly infected cattle that are typically encoutered in Brazil. In this study we have tested cattle sera from animals diagnosed as positive and negative by veterianry inspection for (1) anti-parasite antibodies using metacestodes antigens (T. solium vesicular fluid and T. saginata secretions) and (2) the HP10 secreted antigen of viable metacestodes. The cut-off values were calculated by ROC curve for intense and mild infections conditions, and by the classical method ( for negative samples). The sensitivity and specificity of these diagnostic tests were different depending on the assumed cut-off value and, importantly, whether the infection was mild or intense. In spite of these observations, however, such ELISA assays for serum antibodies and parasite antigens constitute an important tool for epidemiological porposes, and in establishing priorities for the control of bovine cysticercosis.


A cisticercose bovina, uma doença cosmopolita causada pelaTaenia saginata, resulta em perdas econômias devido á desvalorização de carcaças durante o abate. A inspeção sanitária nos frigoríficos, método de diagnóstico de rotina no Brasil, não possui sensibilidade necessária para detectar animais levemente infectados, os quais são tipicamente encontrados no Brasil. Neste estudo testou-se soro de animais diagnosticados positivos e negativos pela inspeção veterinária por (1) anticorpos anti-parasita usando antígenos de metacestóides (fluido vesicular deT. solium e secreções de T. saginata) e (2) antígeno secretado de metacestóides viáveis. Os pontos de corte foram calculados pela curva ROC, considerando condições de intensa e leve infeção, e pelo método clássico ( das amostras negativas). A sensibilidade e a especificidade dos testes diagnósticos foram diferentes dependendo do valor de ponto de corte assumido e, sobretudo, se a infecção era intensa ou leve. Apesar destas observações, no entanto, tanto o ensaio ELISA para anticorpos séricos quanto para antígeno de parasita constituem importante ferramenta para propósitos epidemiológicos e no estabelecimento de prioridades no controle da cisticercose bovina.

SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE